Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Genes Chromosomes Cancer. 2017 Mar 31;56(6):493–500. doi: 10.1002/gcc.22453

Figure 2.

Figure 2

Knockdown of WASF3 in MCF10A cells expressing either endogenous levels (KI#1) of mutant RAS, or overexpressing (G12V) mutant KRAS shows suppression of AKT activation only in the cells overexpressing the mutant RAS (A). ERK1/2 levels were not affected in either cell type. Increases in phosphoactivated AKT (B) was seen in MCF10A cells overexpressing the mutant RAS which was accompanied by increased activation of WASF3. Immunoprecipitation of WASF3 from MDA-MB-231 cells shows the presence of p85 and AKT in the immunocomplex (C). When WASF3 was knocked down in MDA-MB-231 cells, phospho-AKT levels were reduced whereas there was no effect on pAKT when WASF3 was knocked down in SKBR3 cells (D). Overexpression of mutant KRAS (G12V) in T47D cells leads to increased pAKT levels which was more significant when WASF3 was also overexpressed (D).